Cargando…
Jia-Wei-Yu-Ping-Feng-San Attenuates Group 2 Innate Lymphoid Cell-Mediated Airway Inflammation in Allergic Asthma
The incidence of asthma has increased in recent decades. Although corticosteroids and bronchodilators are used in clinical practice, the control of asthma remains a challenge. Allergic asthma is characterized airway inflammation mediated by type 2 immune response. Group 2 innate lymphoid cells (ILC2...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299004/ https://www.ncbi.nlm.nih.gov/pubmed/34305612 http://dx.doi.org/10.3389/fphar.2021.703724 |
_version_ | 1783726176277102592 |
---|---|
author | Xue, Lingna Li, Cui Ge, Guangbo Zhang, Shaoyan Tian, Liming Wang, Yu Zhang, Huiyong Ma, Zifeng Lu, Zhenhui |
author_facet | Xue, Lingna Li, Cui Ge, Guangbo Zhang, Shaoyan Tian, Liming Wang, Yu Zhang, Huiyong Ma, Zifeng Lu, Zhenhui |
author_sort | Xue, Lingna |
collection | PubMed |
description | The incidence of asthma has increased in recent decades. Although corticosteroids and bronchodilators are used in clinical practice, the control of asthma remains a challenge. Allergic asthma is characterized airway inflammation mediated by type 2 immune response. Group 2 innate lymphoid cells (ILC2s) are an important source of type 2 cytokines IL-5 and IL-13, which contribute to the progress of asthma. Jia-Wei-Yu-Ping-Feng-San (JWYPFS), a traditional Chinese medicine, has been widely used to treat asthma in China. In this study we investigated the mechanisms of JWYPFS in the treatment of asthma, especially the effect on ILC2s important in airway inflammation. Female C57BL/6 mice were sensitized and challenged with OVA to establish a model of allergic asthma. Airway hyperresponsiveness was examined by direct airway resistance analysis. Inflammatory cell counts were determined in bronchoalveolar lavage fluid (BALF). Inflammatory cell infiltration and mucus hypersecretion in lung tissue sections was observed by HE and PAS staining, respectively. The numbers and proportions of ILC2s as well as the ILC2s-related transcription factors GATA3, IRF4, and type 2 cytokines were measured in lung tissue samples. Additionally, ILC2s were collected from mouse lung; ILC2s-related cytokines and GATA3 and IRF4 were evaluated after IL-33-induced activation of ILC2s in vitro. Elevated inflammatory cells, mucus secretion, airway hyperresponsiveness and type 2 cytokines in the OVA-treated asthma group indicated that an allergic asthma model had been established. JWYPFS treatment attenuated airway resistance and reduced inflammatory cells including eosinophils, and inhibited mucus production and type 2 cytokines in these asthmatic mice. Moreover, JWYPFS treatment dramatically decreased the numbers and proportions of ILC2s and the mRNA levels of GATA3 and IRF4. In an in vitro experiment JWYPFS significantly suppressed GATA3, IRF4 and type 2 cytokine expression, including IL-5 and IL-13 in IL-33-stimulated ILC2s. JWYPFS alleviates ILC2s-mediated airway inflammation, suggesting that JWYPFS might be an effective agent to treat allergic asthma. |
format | Online Article Text |
id | pubmed-8299004 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82990042021-07-24 Jia-Wei-Yu-Ping-Feng-San Attenuates Group 2 Innate Lymphoid Cell-Mediated Airway Inflammation in Allergic Asthma Xue, Lingna Li, Cui Ge, Guangbo Zhang, Shaoyan Tian, Liming Wang, Yu Zhang, Huiyong Ma, Zifeng Lu, Zhenhui Front Pharmacol Pharmacology The incidence of asthma has increased in recent decades. Although corticosteroids and bronchodilators are used in clinical practice, the control of asthma remains a challenge. Allergic asthma is characterized airway inflammation mediated by type 2 immune response. Group 2 innate lymphoid cells (ILC2s) are an important source of type 2 cytokines IL-5 and IL-13, which contribute to the progress of asthma. Jia-Wei-Yu-Ping-Feng-San (JWYPFS), a traditional Chinese medicine, has been widely used to treat asthma in China. In this study we investigated the mechanisms of JWYPFS in the treatment of asthma, especially the effect on ILC2s important in airway inflammation. Female C57BL/6 mice were sensitized and challenged with OVA to establish a model of allergic asthma. Airway hyperresponsiveness was examined by direct airway resistance analysis. Inflammatory cell counts were determined in bronchoalveolar lavage fluid (BALF). Inflammatory cell infiltration and mucus hypersecretion in lung tissue sections was observed by HE and PAS staining, respectively. The numbers and proportions of ILC2s as well as the ILC2s-related transcription factors GATA3, IRF4, and type 2 cytokines were measured in lung tissue samples. Additionally, ILC2s were collected from mouse lung; ILC2s-related cytokines and GATA3 and IRF4 were evaluated after IL-33-induced activation of ILC2s in vitro. Elevated inflammatory cells, mucus secretion, airway hyperresponsiveness and type 2 cytokines in the OVA-treated asthma group indicated that an allergic asthma model had been established. JWYPFS treatment attenuated airway resistance and reduced inflammatory cells including eosinophils, and inhibited mucus production and type 2 cytokines in these asthmatic mice. Moreover, JWYPFS treatment dramatically decreased the numbers and proportions of ILC2s and the mRNA levels of GATA3 and IRF4. In an in vitro experiment JWYPFS significantly suppressed GATA3, IRF4 and type 2 cytokine expression, including IL-5 and IL-13 in IL-33-stimulated ILC2s. JWYPFS alleviates ILC2s-mediated airway inflammation, suggesting that JWYPFS might be an effective agent to treat allergic asthma. Frontiers Media S.A. 2021-07-09 /pmc/articles/PMC8299004/ /pubmed/34305612 http://dx.doi.org/10.3389/fphar.2021.703724 Text en Copyright © 2021 Xue, Li, Ge, Zhang, Tian, Wang, Zhang, Ma and Lu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Xue, Lingna Li, Cui Ge, Guangbo Zhang, Shaoyan Tian, Liming Wang, Yu Zhang, Huiyong Ma, Zifeng Lu, Zhenhui Jia-Wei-Yu-Ping-Feng-San Attenuates Group 2 Innate Lymphoid Cell-Mediated Airway Inflammation in Allergic Asthma |
title | Jia-Wei-Yu-Ping-Feng-San Attenuates Group 2 Innate Lymphoid Cell-Mediated Airway Inflammation in Allergic Asthma |
title_full | Jia-Wei-Yu-Ping-Feng-San Attenuates Group 2 Innate Lymphoid Cell-Mediated Airway Inflammation in Allergic Asthma |
title_fullStr | Jia-Wei-Yu-Ping-Feng-San Attenuates Group 2 Innate Lymphoid Cell-Mediated Airway Inflammation in Allergic Asthma |
title_full_unstemmed | Jia-Wei-Yu-Ping-Feng-San Attenuates Group 2 Innate Lymphoid Cell-Mediated Airway Inflammation in Allergic Asthma |
title_short | Jia-Wei-Yu-Ping-Feng-San Attenuates Group 2 Innate Lymphoid Cell-Mediated Airway Inflammation in Allergic Asthma |
title_sort | jia-wei-yu-ping-feng-san attenuates group 2 innate lymphoid cell-mediated airway inflammation in allergic asthma |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299004/ https://www.ncbi.nlm.nih.gov/pubmed/34305612 http://dx.doi.org/10.3389/fphar.2021.703724 |
work_keys_str_mv | AT xuelingna jiaweiyupingfengsanattenuatesgroup2innatelymphoidcellmediatedairwayinflammationinallergicasthma AT licui jiaweiyupingfengsanattenuatesgroup2innatelymphoidcellmediatedairwayinflammationinallergicasthma AT geguangbo jiaweiyupingfengsanattenuatesgroup2innatelymphoidcellmediatedairwayinflammationinallergicasthma AT zhangshaoyan jiaweiyupingfengsanattenuatesgroup2innatelymphoidcellmediatedairwayinflammationinallergicasthma AT tianliming jiaweiyupingfengsanattenuatesgroup2innatelymphoidcellmediatedairwayinflammationinallergicasthma AT wangyu jiaweiyupingfengsanattenuatesgroup2innatelymphoidcellmediatedairwayinflammationinallergicasthma AT zhanghuiyong jiaweiyupingfengsanattenuatesgroup2innatelymphoidcellmediatedairwayinflammationinallergicasthma AT mazifeng jiaweiyupingfengsanattenuatesgroup2innatelymphoidcellmediatedairwayinflammationinallergicasthma AT luzhenhui jiaweiyupingfengsanattenuatesgroup2innatelymphoidcellmediatedairwayinflammationinallergicasthma |